CURIS INC CRIS
We are a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4 and FMS-like tyrosine kinase 3 or FLT3. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma, or PCNSL, in combination with ibrutinib, a Bruton Tyrosine Kinase inhibitor or BTK inhibitor and in our recently initiated TakeAim CLL study, a Phase 2 combination study of emavusertib in chronic lymphocytic leukemia, or CLL, with zanubrutinib, a BTK inhibitor. Our monotherapy and combination studies of emavusertib in AML are substantially complete. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration, or FDA, for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. We, through our 2015 collaboration with Aurigene Discovery Technologies Limited, or Aurigene, have the exclusive license to emavusertib (CA-4948).
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.4M | $10.9M | $10.0M | $10.2M | $10.6M | $10.8M | $10.0M | $10.4M | $9.9M | $7.5M |
| R&D | — | — | — | — | — | — | — | — | — | $18.0M |
| SG&A | $14.0M | $16.8M | $18.6M | $19.6M | $17.3M | $12.1M | $11.6M | $14.8M | $14.1M | $15.6M |
| Total operating expenses | $42.3M | $55.5M | $58.4M | $63.2M | $52.7M | $35.7M | $34.4M | $39.8M | $59.7M | $65.6M |
| Operating income | -$5.7M | -$44.5M | -$48.3M | -$53.0M | -$42.1M | -$24.9M | -$24.4M | -$29.3M | -$49.8M | -$58.0M |
| Interest expense | — | — | — | — | $0 | $0 | $791.0K | $3.9M | $4.0M | $2.8M |
| Pre-tax income | -$7.6M | -$43.4M | — | — | — | — | — | — | — | — |
| Income tax | $0 | $0 | — | — | — | — | — | — | — | — |
| Net income | -$7.6M | -$43.4M | -$47.4M | -$56.7M | -$45.4M | -$29.9M | -$32.1M | -$32.6M | -$53.3M | -$60.4M |
| EPS, basic | -0.58 | -6.88 | -8.96 | -12.14 | 0.50 | -0.61 | -0.97 | — | — | — |
| EPS, diluted | -0.58 | -6.88 | -8.96 | -12.14 | 0.50 | -0.61 | -0.97 | -0.98 | -1.79 | -0.45 |
| Shares, diluted (wtd. avg.) | $13.2M | $6.3M | $5.3M | $4.7M | $91.6M | $48.7M | $33.2M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.1M | $20.0M | $27.2M | $20.3M | $40.7M | $130.4M | $16.4M | $23.8M | $38.4M | $26.0M |
| Short-term investments | — | $0 | $29.7M | $66.0M | $75.9M | $38.9M | $5.1M | $634.0K | $21.9M | $18.4M |
| Receivables | $0 | $3.3M | $2.8M | $3.0M | $3.2M | $3.0M | $3.2M | $2.9M | $3.1M | $2.5M |
| Total current assets | $6.9M | $26.4M | $60.9M | $92.1M | $122.4M | $172.8M | $25.0M | $28.0M | $64.3M | $48.2M |
| Property, plant and equipment | $62.0K | $231.0K | $434.0K | $689.0K | $505.0K | $663.0K | $154.0K | $267.0K | $366.0K | $413.0K |
| Goodwill | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M |
| Total assets | $20.0M | $41.3M | $77.3M | $108.8M | $162.3M | $204.4M | $35.1M | $37.4M | $73.8M | $57.8M |
| Accounts payable | $5.6M | $3.0M | $3.2M | $3.2M | $6.4M | $4.2M | $4.5M | $2.9M | $5.4M | $5.9M |
| Short-term debt | $0 | $7.6M | $8.5M | — | $0 | $557.0K | $0 | $6.9M | $5.9M | $4.9M |
| Total current liabilities | $14.1M | $19.0M | $22.0M | $10.0M | $13.4M | $10.1M | $6.5M | $13.2M | $14.1M | $13.5M |
| Long-term debt | — | — | — | — | — | — | $900.0K | $28.6M | $35.7M | $14.9M |
| Total liabilities | $14.5M | $47.3M | $57.6M | $62.3M | $71.6M | $73.7M | $69.0M | $41.9M | $49.8M | $28.5M |
| Retained earnings | -$1.25B | -$1.24B | -$1.20B | -$1.15B | -$1.09B | -$1.05B | -$1.02B | -$984.8M | -$952.3M | -$898.9M |
| Total equity | $5.5M | -$6.0M | $19.7M | $46.6M | $90.7M | $130.7M | -$33.9M | -$4.5M | $24.0M | $29.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$27.2M | -$39.6M | -$38.4M | -$54.3M | -$37.6M | -$25.7M | -$26.2M | -$30.1M | -$48.4M | -$35.8M |
| Stock-based compensation | $4.0M | $5.9M | $6.0M | $6.8M | $5.3M | $2.7M | $2.7M | $3.9M | $5.4M | $4.3M |
| Capital expenditure | — | — | $0 | $416.0K | $0 | $677.0K | $41.0K | $85.0K | $188.0K | $329.0K |
| Investing cash flow | $2.5M | $29.4M | $37.8M | $33.0M | -$47.9M | -$49.0M | -$4.5M | $21.4M | -$3.6M | $30.1M |
| Financing cash flow | $9.8M | $3.4M | $7.6M | $867.0K | -$4.2M | $188.8M | $23.3M | -$6.0M | $64.2M | -$1.4M |
| Buybacks | — | — | — | — | — | — | — | — | $1.5M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001108205-26-000053.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |